HIV PrEP Safe in 2nd Trimester for Negative Pregnant Women

For pregnant women at risk of HIV, starting preventative treatment during the second trimester appears to be safe, according to recent findings. Both the monthly dapivirine vaginal ring and daily oral pre-exposure prophylaxis (PrEP) – a combination of tenofovir disoproxil fumarate and emtricitabine – showed no safety concerns when initiated during this period, offering potential options for a population facing heightened vulnerability.

Increased HIV Risk During Pregnancy

Pregnant individuals are estimated to be three times more likely to acquire HIV through sexual intercourse compared to their non-pregnant counterparts. This increased susceptibility underscores the critical necessitate for effective prevention strategies tailored to this population. The findings, presented at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, address a significant gap in data regarding the use of these preventative measures during pregnancy. While previous studies showed some participants became pregnant while using the dapivirine ring and discontinued use without any adverse effects, a dedicated study focusing on this specific group was lacking.

The research, conducted across Malawi, South Africa, Uganda and Zimbabwe by the Microbicide Trials Network, an NIAID-funded international research network, provides crucial evidence for healthcare providers and expectant mothers. The NIAID also received co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Mental Health for this important work.

Understanding PrEP Options

Pre-exposure prophylaxis, or PrEP, involves taking medication before potential exposure to HIV to prevent infection. Currently, two primary methods are available: daily oral PrEP and the dapivirine vaginal ring. Oral PrEP combines tenofovir disoproxil fumarate and emtricitabine, taken as a daily tablet. The dapivirine ring, approved in several African countries and recommended by the World Health Organization (WHO) for HIV prevention, is a flexible silicone ring that slowly releases the antiretroviral drug dapivirine into the vagina and is replaced monthly by the user. Both methods aim to reduce the risk of HIV acquisition, but their safety profiles during pregnancy required further investigation.

Study Details and Findings

The study specifically examined the safety of initiating either the dapivirine ring or oral PrEP during the second trimester of pregnancy in women testing negative for HIV. Details regarding the precise study design, sample size, and specific endpoints were not immediately available in the provided sources, but the presented findings indicate no concerning safety signals were observed with either method. This is particularly important as data on dapivirine ring use during pregnancy had been limited previously.

The findings build on existing knowledge about the effectiveness of both PrEP methods in preventing HIV transmission. NIAID highlights that both the ring and oral PrEP are safe and effective as HIV pre-exposure prophylaxis (PrEP) among women. However, this modern research specifically addresses the safety of starting these regimens during pregnancy, a previously understudied area.

What So for Pregnant Women and Healthcare Providers

These findings offer reassurance to pregnant women at risk of HIV and their healthcare providers. Knowing that both the dapivirine ring and oral PrEP are safe to initiate during the second trimester expands the options available for HIV prevention during pregnancy. This is particularly relevant in regions with high HIV prevalence and limited access to comprehensive healthcare services. It’s important to remember that this research focuses on women who tested negative for HIV; it does not address the use of these methods in women already living with HIV.

The study does not dictate which method is preferable, leaving that decision to be made collaboratively between the patient and their clinician, considering individual circumstances, preferences, and access to care. Factors such as adherence, potential side effects, and cost may all influence the choice of PrEP method.

Contextualizing Risk and Prevention

While PrEP is highly effective when taken as prescribed, it’s crucial to understand that it doesn’t eliminate the risk of HIV acquisition entirely. Adherence to the chosen regimen is paramount for optimal protection. PrEP should be used in conjunction with other HIV prevention strategies, such as safe sex practices and regular HIV testing.

The increased vulnerability of pregnant women to HIV infection is linked to hormonal and immunological changes that occur during pregnancy, which can weaken the immune system and increase susceptibility to infection. This underscores the importance of proactive prevention measures for this population.

Next Steps: Ongoing Research and Guidance Updates

The Microbicide Trials Network and NIAID continue to conduct research to further refine HIV prevention strategies, including studies evaluating the long-term safety and effectiveness of PrEP methods in pregnant women. Ongoing surveillance and data analysis will be crucial for monitoring the impact of these findings on HIV incidence rates and informing future guidance updates.

Healthcare providers should stay informed about the latest recommendations from organizations like the WHO and national health authorities regarding PrEP use in pregnancy. Medscape reports that this research confirms the safety of starting PrEP in the second trimester, but continuous monitoring and evaluation are essential to ensure optimal patient care. Further research may also explore the potential benefits of initiating PrEP earlier in pregnancy or extending its use postpartum.